Cardiff Oncology, Inc. · NASDAQ:CRDF
Cardiff Oncology — Q3 2023 Earnings Presentation
10 slides from Cardiff Oncology's earnings presentation, Nov 2, 2023
Slide 1: Q3 2023 Financial Results and Business Update
NOVEMBER 2, 2023 Q3 2023 Financial Results and Business Update
Slide 2: Forward-looking statements
2 Forward-looking statements CERTAIN STATEMENTS IN THIS PRESENTATION ARE FORWARD-LOOKING within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other s
Slide 3: Q3 2023 announcements were transformational for Cardiff Oncology
3 Q3 2023 announcements were transformational for Cardiff Oncology • Data from 2nd line Phase 1b/2 trial in KRAS-mutated mCRC • Conclusions from Type C meeting with FDA • Expansion of Pfizer relationship August data release • Metastatic pancreatic ductal adenocarcinoma (mPDAC) • Small cell lung canc
Slide 4: Cardiff Oncology has several core strengths
4 Cardiff Oncology has several core strengths to create value 1. Onvansertib’s clinical signal of efficacy and tolerability 2. Onvansertib’s novel approach to PLK1 inhibition 3. Onvansertib can combine with 1st / 2nd line SoC regimens that target large populations 4. Third party support and validati
Slide 5: Cardiff Oncology is focused on three objectives
5 Cardiff Oncology is focused on three objectives to create value 1. Lead program: RAS-mut mCRC Generate data from the 1st line RAS-mutated mCRC CRDF-004 trial in mid-2024 2. Earlier-stage programs: Pancreatic, SCLC, TNBC 3. Pipeline expansion: Preclinical programs Develop through investigator-initi
Slide 6: Lead program: RAS-mut mCRC
6 Cardiff Oncology is focused on three objectives to create value 1. Lead program: RAS-mut mCRC Generate data from the 1st line RAS-mutated mCRC CRDF-004 trial in mid-2024 • Phase 1b/2 data from 2nd line KRAS-mut mCRC – 73% ORR in bev naïve patients vs. ~25% for historical controls – 15-month median
Slide 7: Cardiff Oncology is focused on three objectives
7 Cardiff Oncology is focused on three objectives to create value 1. Lead program: RAS-mut mCRC Generate data from the 1st line RAS-mutated mCRC CRDF-004 trial in mid-2024 2. Earlier-stage programs: Pancreatic, SCLC, TNBC 3. Pipeline expansion: Preclinical programs Develop through investigator-initi
Slide 8: Onvansertib/paclitaxel combination achieved significant tumor regression
8 Onvansertib/paclitaxel combination achieved significant tumor regression * Onvansertib (PO) 45mg/kg, 5 times/week; Paclitaxel (IP) dose 20 mg/kg, weekly. Mean ± SEM are represented. Complete response defined as at least 1 tumor measurement<10mm3. Unpaired t-test was used to compare relative tumor
Slide 9: Our financial position is strong as of Q3 2023
9 Our financial position is strong as of Q3 2023 We expect clinical data from our 1st line RAS-mutated mCRC trial in mid-2024 September 30, 2023 cash and investments* $81.4M Q3 2023 net cash used in Operating Activities* $8.0M Runway with current cash extends into 2025 * Financial information above
Slide 10: Cardiff Oncology has several core strengths
10 Cardiff Oncology has several core strengths to create value 1. Onvansertib’s clinical signal of efficacy and tolerability 2. Onvansertib’s novel approach to PLK1 inhibition 3. Onvansertib can combine with 1st / 2nd line SoC regimens that target large populations 4. Third party support and validat